𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost of a quality-adjusted life year in liver transplantation: The influence of the indication and the model for end-stage liver disease score

✍ Scribed by Fredrik Åberg; Suvi Mäklin; Pirjo Räsänen; Risto P. Roine; Harri Sintonen; Anna-Maria Koivusalo; Krister Höckerstedt; Helena Isoniemi

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
151 KB
Volume
17
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis

Cost issues in liver transplantation (LT) have received increasing attention, but the cost-utility is rarely calculated. We compared costs per quality-adjusted life year (QALY) from the time of placement on the LT waiting list to 1 year after transplantation for 252 LT patients and to 5 years after transplantation for 81 patients. We performed separate calculations for chronic liver disease (CLD), acute liver failure (ALF), and different Model for End-Stage Liver Disease (MELD) scores. For the estimation of QALYs, the health-related quality of life was measured with the 15D instrument. The median costs and QALYs after LT were €141,768 and 0.895 for 1 year and €177,618 and 3.960 for 5 years, respectively. The costs of the first year were 80% of the 5-year costs. The main cost during years 2 to 5 was immunosuppression drugs (59% of the annual costs). The cost/QALY ratio improved from €158,400/QALY at 1 year to €44,854/QALY at 5 years, and the ratio was more beneficial for CLD patients (€42,500/QALY) versus ALF patients (€63,957/QALY) and for patients with low MELD scores versus patients with high MELD scores. Although patients with CLD and MELD scores > 25 demonstrated markedly higher 5-year costs (€228,434) than patients with MELD scores < 15 (€169,541), the cost/QALY difference was less pronounced (€59,894/QALY and €41,769/QALY, respectively). The cost/QALY ratio for LT appears favorable, but it is dependent on the assessed time period and the severity of the liver disease. Liver Transpl 17:1333-1343, 2011. V C 2011 AASLD.

📜 SIMILAR VOLUMES

Model for end-stage liver disease except
Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score–based liver allocation system
✍ Claire Francoz; Jacques Belghiti; Denis Castaing; Olivier Chazouillères; Jean-Ch 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

Model for End-Stage Liver Disease (MELD) score-based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis. Except for extreme values, high pretransplant MELD scores do not signific

Liver transplantation cost in the model
Liver transplantation cost in the model for end-stage liver disease era: Looking beyond the transplant admission
✍ Paula Buchanan; Nino Dzebisashvili; Krista L. Lentine; David A. Axelrod; Mark A. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

We examined the relationship between the total cost incurred by liver transplantation (LT) recipients and their Model for End-Stage Liver Disease (MELD) score at the time of transplant. We used a novel database linking billing claims from a large private payer with the Organ Procurement and Transpla

Renal outcomes after liver transplantati
Renal outcomes after liver transplantation in the model for end-stage liver disease era
✍ Pratima Sharma; Kathy Welch; Richard Eikstadt; Jorge A. Marrero; Robert J. Fonta 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

The proportion of patients undergoing liver transplantation (LT) with renal insufficiency has significantly increased in the Model for End-Stage Liver Disease (MELD) era. This study was designed to determine the incidence and predictors of post-LT chronic renal failure (CRF) and its effect on patien

Increased model for end-stage liver dise
Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs
✍ Matthew R. Foxton; Mohammad A. B. Al-Freah; Andrew J. Portal; Elizabeth Sizer; W 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

Organ allocation based on Model for End-Stage Liver Disease (MELD) resulted in decreased waiting list mortality in the United States. However, reports suggest an increase in resource utilization as a consequence of this. The aim of this study is to assess the correlation of MELD at transplant with p

A systematic review of the performance o
A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation
✍ Evangelos Cholongitas; Laura Marelli; Vibhakorn Shusang; Marco Senzolo; Keith Ro 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 1 views

The Model for End-Stage Liver Disease (MELD) score is now used for allocation in liver transplantation (LT) waiting lists, replacing the Child-Turcotte-Pugh (CTP) score. However, there is debate as whether it is superior to CTP score to predict mortality in patients with cirrhosis on the LT waiting

Survival after liver transplantation for
Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre–model for end-stage liver disease eras and the independent impact of hepatitis C virus
✍ Paul J. Thuluvath; Anurag Maheshwari; Nimisha P. Thuluvath; Geoffrey C. Nguyen; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB 👁 1 views

It has been suggested that hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC) may have worse outcomes after liver transplantation (LT) because of more aggressive tumor biology. In this study, we determined the post-LT survival of HCC patients with and without HCV using United Netwo